Of particular interest are SGLT2 inhibitors that have been proven to be efficient in reducing liver fat content, AST/ALT levels, and even liver stiffness in several trials, making this class of drugs one of the most promising future treatments for the specific indication of NAFLD. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.